Term ends Nov 27, 2026 · High confidence
No current holder resolved from the recorded chain.
Filed May 4, 2012 as application 29/420,128 · Granted Nov 27, 2012
Base term, 14 years from grant
Today
2012
2026
Clock starts
Nov 27, 2012
Nov 27, 2012
Term ends
Nov 27, 2026
Nov 27, 2026
base term
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
None
Terminal disclaimer
No disclaimer on this record.
14 years from grant
Base term
No maintenance fees are payable on this kind of patent.
2
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its base term, 14 years from grant, with no adjustment for prosecution delay. No maintenance fees are payable on this kind of patent. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 14 years from grant | Granted Nov 27, 2012 | Nov 27, 2026 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Computed term end | The steps above, in order | Nov 27, 2026 | High confidence |
This family
| Application 29/401,990 | Abandoned not computed | not computed |
| US D671,580 | this patent Nov 2026 | Nov 2026 |
The applications whose file history this site holds. The family may have others.
Assignments
The 40 most recent of 92 recorded documents are shown; the 52 earliest are not. Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Apr 8, 2025 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | Bausch Health, Canada Inc. / Sante Bausch, Canada Inc. | Release of Security Interest |
| Apr 8, 2025 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | ICN Polfa Rzeszow Spolka Akcyjna (A/K/A ICN Polfa Rzeszow S.A.) | Release of Security Interest |
| Apr 8, 2025 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | Orapharma, Inc. | Release of Security Interest |
| Apr 8, 2025 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | Przedsiebiorstwo Farmaceutyczne Jelfa Spolka Akcyjna (A/K/A Przedsiebiorstwo Farmaceutyczne Jelfa S.A.) | Release of Security Interest |
| Apr 8, 2025 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | Solta Medical Dutch Holdings B.V. | Release of Security Interest |
| Apr 8, 2025 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | V-Bac Holding Corp. | Release of Security Interest |
| Apr 8, 2025 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | VRX Holdco LLC | Release of Security Interest |
| Apr 8, 2025 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | 1261229 B.C. Ltd. | Release of Security Interest |
| Apr 8, 2025 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | 1530065 B.C. Ltd. | Release of Security Interest |
| Jul 1, 2025 Reel 71773, frame 871 | Bausch & Lomb Incorporated; Alden Optical Laboratories, Inc.; Bausch + Lomb Ireland Limited | Citibank, N.A., as Notes Collateral Agent | Patent Security Agreement |
| Aug 14, 2025 Reel 72469, frame 91 | Citibank, N.A., as Resigning Agent | JPMorgan Chase Bank, N.A., as Successor Agent | Assignment of Security Interest in Patents Previously Recorded at Reel/Frame (059913/0548) |
| Nov 20, 2025 Reel 73637, frame 1 | The Bank of New York Mellon, as Notes Collateral Agent | Aton Pharma, Inc.; Bausch & Lomb Incorporated; Bausch & Lomb Pharma Holdings Corp.; Commonwealth Laboratories, LLC; Dow Pharmaceutical Sciences, Inc.; Ecr Pharmaceuticals Co., Inc.; Laboratoire Chauvin S.A.S.; Medicis Pharmaceutical Corporation; Onpharma Inc.; Orapharma, Inc.; Precision Dermatology, Inc.; Salix Pharmaceuticals, Ltd.; Salix Pharmaceuticals, Inc.; Santarus, Inc.; Solta Medical, Inc.; Synergetics USA, Inc.; Technolas Perfect Vision GmbH; Valeant Canada LP; Valeant Pharmaceuticals International; Valeant Pharmaceuticals International, Inc.; Valeant Pharmaceuticals North America LLC; Wirra IP Pty Limited; Valeant Pharma Poland SP. Z O.O.; Valeant Pharmaceuticals Luxembourg S.A R.L.; Valeant Pharmaceuticals Ireland Limited | Release of Security Interest |
| Nov 20, 2025 Reel 73654, frame 242 | The Bank of New York Mellon, as Notes Collateral Agent | Bausch & Lomb Incorporated; Bausch Health US, LLC; Solta Medical, Inc.; Medicis Pharmaceutical Corporation; Salix Pharmaceuticals, Inc.; Salix Pharmaceuticals, Ltd.; Santarus, Inc.; Orapharma, Inc.; Precision Dermatology, Inc.; Bausch Health Americas, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Aton Pharma, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Bausch & Lomb Incorporated | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Bausch & Lomb Pharma Holdings Corp. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Commonwealth Laboratories, LLC | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Dow Pharmaceutical Sciences, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Ecr Pharmaceuticals Co., Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Laboratoire Chauvin S.A.S. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Medicis Pharmaceutical Corporation | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Onpharma Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Orapharma, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Precision Dermatology, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Salix Pharmaceuticals, Ltd. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Salix Pharmaceuticals, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Santarus, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Solta Medical, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Synergetics USA, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Technolas Perfect Vision GmbH | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Valeant Canada LP | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Valeant Pharmaceuticals International | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Valeant Pharmaceuticals International, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Valeant Pharmaceuticals North America LLC | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Wirra IP Pty Limited | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Valeant Pharma Poland SP. Z O.O. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Valeant Pharmaceuticals Luxembourg S.A R.L. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Valeant Pharmaceuticals Ireland Limited | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Bausch Health Americas, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Bausch Health US, LLC | Release of Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center
No maintenance fees are payable on this kind of patent, so the record carries no fee events.
What's changing
Nov 2026
Term ends Nov 27, 2026. No maintenance fees are payable on this kind of patent
Citations
31
later US patents cite this one
That is above the median of design patents granted in 2012 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.